预约演示
更新于：2025-04-17
Tolvaptan
托伐普坦
更新于：2025-04-17
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (2009-05-19), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (日本) |
登录后查看时间轴
结构/序列
分子式C26H25ClN2O3 |
InChIKeyGYHCTFXIZSNGJT-UHFFFAOYSA-N |
CAS号150683-30-0 |
关联
256
项与 托伐普坦 相关的临床试验CTR20250164
托伐普坦口崩片在中国健康人群中空腹和餐后状态下单次给药的人体生物等效性临床试验
ACTRN12624000756527
A randomised multi-centre trial of Tolvaptan vs. Urea for therapy of hyponatraemia after failure of fluid restriction in hospital inpatients
CTR20242495
托伐普坦片在健康受试者中单次口服给药、随机、开放、两制剂生物等效性试验
100 项与 托伐普坦 相关的临床结果
登录后查看更多信息
100 项与 托伐普坦 相关的转化医学
登录后查看更多信息
100 项与 托伐普坦 相关的专利（医药）
登录后查看更多信息
1,775
项与 托伐普坦 相关的文献（医药）2025-06-01BIOCHEMICAL PHARMACOLOGY
Therapeutic opportunities in polycystic kidney and liver disease through extracellular matrix dynamics
Article
作者: Bravo, Susana ; Lamas-González, Olaya ; Nuñez-González, Laura ; Cordido, Adrian ; García-González, Miguel A ; Banales, Jesus M ; Vizoso-González, Marta ; Díaz, Candido
Autosomal Dominant and Autosomal Recessive Polycystic Kidney Disease (ADPKD and ARPKD) are, respectively, common and rare forms of polycystic disorders, characterized by the formation and progressive growth of cysts from tubules in the kidneys and bile ducts in the liver. Alterations in the extracellular matrix (ECM) and in the activity of matrix metalloproteases (MMPs), both associated with fibrosis, have been shown to be important factors in cystic growth and progression of these diseases. We used tandem mass spectrometry (LC-MS/MS) to identify the most enriched proteins and pathways in an orthologous rapidly progressive mouse model of ADPKD: Pkd1flox/floxTamCre. This information was used to discover and validate novel therapeutic targets in orthologous models of ADPKD (Pkd1flox/floxTamCre) and ARPKD (Pkdh1del3-4/del3-4). ECM related pathways and expression levels of MMPs were among the most dysregulated cellular processes in polycystic kidney and liver. Selective inhibition of MMPs by marimastat (MTT) altered the ECM response and resulted in inhibition of collecting duct-derived cyst growth, delay of global kidney cyst progression and rescue of liver phenotype by normalized MMPs expression and significant reduction in fibrosis. This phenotypic improvement was further enhanced by treatment of MTT and tolvaptan, indicating an additive benefit to targeting the fibrotic and growth pathways in cysts. As conclusion, targeting of MMPs are important in ECM dysregulation and offers a new potential therapeutic strategy for both kidney and bile duct derived fibrocystic disease in ADPKD and ARPKD. Such approaches can have additive benefits with other treatment approaches, such as tolvaptan.
2025-05-01NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
The potential effectiveness of tolvaptan in critically ill patients including cardiac and noncardiac populations: a retrospective observational study
Article
作者: Sugo, Yuki ; Yamazaki, Yuma ; Niwa, Hidetomo ; Ishiyama, Erina ; Hirota, Kazuyoshi ; Hori, Mirei
We investigated the potential diuretic effectiveness of the selective arginine vasopressin 2 receptor antagonist tolvaptan in critically ill patients including cardiac and noncardiac populations. This was a single-center retrospective observational study. We analyzed the data of our hospital's critically ill adult patients (n = 473) including noncardiac as well as cardiac populations who had an ICU stay ≥ 4 days in 2019-2020 and who did not undergo renal transplantation or permanent renal replacement therapy before their ICU admission. Adjusting for several confounders (the patients' disease severity, comorbidities including cardiac disease, and diuretics used), we estimated the predictors for the patients whose daily urine volume had increased by up to twofold or more compared to the minimal value (the primary endpoint) by applying a multivariable logistic regression model. We also investigated tolvaptan's effect on time-course changes in the serum creatine (sCr) level (the secondary endpoint) by using a generalized estimating equation model. Tolvaptan use was significantly correlated with increased urine volume (odds ratio [OR] 1.86, 95%CI 1.13-3.06, p = 0.015) but was not significantly associated with time-course changes in the sCr level: beta estimator [95%CI], 0.07 [- 0.01 to 0.15], p = 0.08. Tolvaptan independently increased the urine volume, apparently without worsening the renal function in critically ill patients including cardiac and noncardiac populations.
2025-04-01Radiology case reports
Multisystemic impact of autosomal dominant polycystic kidney disease: A case report highlighting renal, hepatic, and neurological involvement
Article
作者: Faiyaz, Ahmed Fahim ; Khalil, Ibrahim ; Hossain, Md Imran ; Akter, Mahmuda
We present a case of a 64-year-old male with Autosomal Dominant Polycystic Kidney Disease (ADPKD), characterized by systemic involvement, including renal, hepatic, and neurological complications. The patient presented with persistent micturition difficulties, hematuria, and abdominal pain, compounded by hypertension and chronic obstructive pulmonary disease. Imaging revealed bilateral renal enlargement with hemorrhagic cysts, a kidney stone, and hepatic cysts causing hepatomegaly. Neurological evaluation identified chronic and recent intracerebral hemorrhages associated with poorly controlled hypertension, underscoring ADPKD's multisystem impact. ADPKD, caused by PKD1 or PKD2 mutations, often leads to progressive renal dysfunction, hypertension, and extrarenal manifestations such as hepatic cysts and intracranial aneurysms. Advances like tolvaptan demonstrate efficacy in slowing renal disease progression, while somatostatin analogs offer promise for hepatic cyst management. This case emphasizes the necessity of a multidisciplinary approach, including strict blood pressure control, regular imaging, and pharmacological intervention, to address ADPKD's complexities and optimize patient outcomes. Early diagnosis and vigilant monitoring remain crucial for preventing complications and enhancing quality of life. This report underscores the importance of integrated care in managing ADPKD, highlighting emerging therapies and the ongoing need for personalized treatment strategies in such challenging cases.
100 项与 托伐普坦 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 腹水 | 日本 | 2017-02-28 | |
| 常染色体显性多囊肾病 | 日本 | 2014-03-24 | |
| 心源性水肿 | 日本 | 2011-01-05 | |
| 水肿 | 日本 | 2010-10-27 | |
| ADH分泌不当综合征 | 欧盟 | 2009-08-02 | |
| ADH分泌不当综合征 | 冰岛 | 2009-08-02 | |
| ADH分泌不当综合征 | 列支敦士登 | 2009-08-02 | |
| ADH分泌不当综合征 | 挪威 | 2009-08-02 | |
| 低钠血症 | 美国 | 2009-05-19 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 常染色体隐性遗传性多囊肾 | 临床3期 | 美国 | 2022-07-01 | |
| 常染色体隐性遗传性多囊肾 | 临床3期 | 比利时 | 2022-07-01 | |
| 常染色体隐性遗传性多囊肾 | 临床3期 | 德国 | 2022-07-01 | |
| 常染色体隐性遗传性多囊肾 | 临床3期 | 波兰 | 2022-07-01 | |
| 常染色体隐性遗传性多囊肾 | 临床3期 | 西班牙 | 2022-07-01 | |
| 常染色体隐性遗传性多囊肾 | 临床3期 | 英国 | 2022-07-01 | |
| 音量过载 | 临床3期 | 日本 | 2018-03-07 | |
| 慢性肾病 | 临床3期 | 美国 | 2014-05-01 | |
| 慢性肾病 | 临床3期 | 阿根廷 | 2014-05-01 | |
| 慢性肾病 | 临床3期 | 澳大利亚 | 2014-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 1,676 | 製選鑰淵獵積憲鹹憲壓(觸憲觸鹹壓簾積製憲蓋) = 9.6% 積窪鏇糧艱範夢糧憲構 (餘憲遞衊鏇觸網簾顧膚 ) 更多 | 积极 | 2025-02-14 | |||
临床3期 | 60 | 獵夢鏇觸觸憲淵壓鑰顧 = 齋夢艱餘壓遞構網夢淵 顧蓋窪鑰構憲淵醖鹽蓋 (膚蓋網製積簾願膚鑰淵, 遞觸簾簾遞選憲選繭繭 ~ 鏇鏇顧糧廠繭餘選糧糧) 更多 | - | 2024-08-23 | |||
N/A | 肝硬化 neutrophil gelatinase-associated lipocalin (uNGAL) | 86 | 遞艱觸選顧糧遞積構憲(積觸憲壓糧繭鏇鹹遞獵) = 糧構憲選鑰糧鹽範鬱顧 繭鬱鹽鏇醖鑰選夢鹽繭 (願廠簾鑰鑰網鬱鑰淵夢 ) 更多 | - | 2023-11-10 | ||
N/A | - | 1 | 蓋淵憲憲築網廠鹽餘簾(構築觸醖淵蓋膚鬱鏇願) = 積憲願夢獵觸顧鹹鏇壓 製憲壓鬱願選蓋淵醖觸 (廠餘醖襯鏇構鹹餘餘艱 ) | 积极 | 2023-10-05 | ||
N/A | 846 | 選觸鹽醖積築遞簾範艱(簾簾顧鬱獵壓鹽鹽壓膚) = 鏇簾積鏇壓衊窪網鑰鏇 鑰衊獵繭鹹蓋積壓壓繭 (窪鹹鏇遞淵廠製築蓋壓 ) 更多 | - | 2023-08-27 | |||
N/A | - | 簾簾壓觸積積築鹽廠製(網壓築壓選獵繭獵築觸) = 夢窪艱鏇鏇願衊繭願糧 遞願餘鑰淵網製簾鑰鬱 (衊糧獵憲艱憲鬱繭製獵 ) 更多 | - | 2023-06-22 | |||
Placebo | 簾簾壓觸積積築鹽廠製(網壓築壓選獵繭獵築觸) = 築獵獵窪網鬱窪鹽壓選 遞願餘鑰淵網製簾鑰鬱 (衊糧獵憲艱憲鬱繭製獵 ) 更多 | ||||||
N/A | 523 | 餘選鹽膚築夢艱膚襯構(繭顧鬱淵製獵餘衊遞顧) = 51% 遞簾顧繭鏇蓋鏇繭憲範 (艱鏇願網鏇網窪糧鏇簾 ) 更多 | 积极 | 2023-06-14 | |||
N/A | 75 | 繭獵糧網築窪衊憲窪範(廠構範簾築廠鑰窪艱淵) = A significant increase (p< 0.0001) in 24-h urine volume (138%) occurred only immediately after therapy initiation with no further significant increase during updosing in the complete and longitudinal cohort 製鑰艱顧齋鬱鏇選積積 (艱鹽鬱鑰鑰蓋廠簾窪繭 ) 更多 | 积极 | 2023-06-14 | |||
临床3期 | 83 | 顧網獵淵壓範鬱廠鑰齋(廠顧觸願鹹壓範齋壓淵) = 12%, 31% 製鬱壓廠鬱鑰獵鏇蓋齋 (構糧憲襯顧製夢夢範淵 ) 更多 | 积极 | 2023-06-14 | |||
Placebo | |||||||
临床2/3期 | - | 繭選築夢鬱鑰蓋觸憲築(廠觸鏇艱積網壓遞鬱構) = 膚餘構淵蓋鏇網衊製構 願遞鏇築夢壓鑰築構願 (夢簾廠願壓鬱餘淵夢選 ) | - | 2023-06-01 | |||
Non-tolvaptan standard of care | 繭選築夢鬱鑰蓋觸憲築(廠觸鏇艱積網壓遞鬱構) = 觸網鑰齋獵襯鏇齋鏇餘 願遞鏇築夢壓鑰築構願 (夢簾廠願壓鬱餘淵夢選 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用